Relief’s Inhaled Therapy RLF-100 Earns FDA’s Orphan Drug Status

Relief’s Inhaled Therapy RLF-100 Earns FDA’s Orphan Drug Status

302895

Relief’s Inhaled Therapy RLF-100 Earns FDA’s Orphan Drug Status

The U.S. Food and Drug Administration has granted orphan drug designation to RLF-100 (aviptadil), Relief Therapeutics’ investigational inhaled therapy for sarcoidosis. Such status is given to treatment candidates with the potential to be safe and effective in rare diseases — defined in the U.S. as those affecting fewer than 200,000 people — that have no approved treatments, or in cases in which the potential therapy shows significant benefit over existing treatments. The designation is meant…

You must be logged in to read/download the full post.